TreeFrog Therapeutics
Cell Therapy for All
TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients.
TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality.
Bringing together over 70 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline of stem cell-based therapies in the field of neurodegeneration, cardio-metabolic disorders, and immuno-oncology. In 2022, the company will open technological hubs in Boston, USA, and Kobe, Japan, to drive the adoption of C-Stem and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.
TreeFrog Therapeutics I iPS-derived cell therapies I Cell Therapy for all
TreeFrog Therapeutics is a cell therapy biotech based in Bordeaux, France. TreeFrog advances a pipeline of allogeneic cell therapies based on human induced pluripotent stem cells (hiPSCs) and develops a breakthrough technology – C-Stem – allowing to scale-up cell therapy manufacturing in bioreactors thus reducing cell therapy costs, to improve cell quality to ensure the genomic safety of cell therapy products, and to enhance the efficacy of cellular therapies through a delivery approach based on 3D microtissues containing mature cell phenotypes (in contrast with cell therapies based single-cell suspensions of progentiors). C-Stem enables exponential iPS cell amplification with high viability, pluripotency and genomic integrity in large-scale stirred-tank bioreactors, thus producing commercial-size single-batches of iPS of over 10 billions cells. Our iPS platform also enables direct differentiation of human pluripotent stem cells into the desired cell type in a ready-to-graft 3D microtissue format. The company founded by Kevin Alessandri & Maxime Feyeux, aims at providing access to safe, efficient and affordable cell therapies for all.
